Trial
NCT02834247
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Calithera Biosciences, Inc
Collaborators
—
Condition
Triple-Negative Breast Neoplasms
Intervention
TAK-659
Why stopped
Insufficient efficacy of drug; no safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-08